<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542304</url>
  </required_header>
  <id_info>
    <org_study_id>56566</org_study_id>
    <nct_id>NCT04542304</nct_id>
  </id_info>
  <brief_title>Efficacy of Diuretics in Kidney Disease</brief_title>
  <official_title>Efficacy of Diuretics in Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy of diuretics in patients with chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with chronic kidney disease will undergo two 1-week study periods (diuretic&#xD;
      versus placebo) separated by 1-2 weeks of washout in a cross-over design. Blood and urine&#xD;
      samples will be collected at the end of each study period to determine the effect on urine&#xD;
      output and to assess the kidney clearance and levels of uremic solute. Participants will&#xD;
      weigh themselves daily and complete quality of life questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urine output</measure>
    <time_frame>Change from baseline urine output at 1 week for each study arm</time_frame>
    <description>average volume of urine produced in 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in kidney clearance of uremic solutes</measure>
    <time_frame>Change from baseline kidney clearance of uremic solutes at 1 week for each study arm</time_frame>
    <description>kidney clearance of uremic solutes in ml/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life questionnaire score</measure>
    <time_frame>Change from baseline quality of life score at 1 week for each study arm</time_frame>
    <description>Kidney Disease Quality of Life 36 Questionnaire (KDQOL36)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Metolazone then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Metolazone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metolazone</intervention_name>
    <description>Participants will be given a metolazone for the 1-week study period.</description>
    <arm_group_label>Metolazone then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be given a placebo for the 1-week study period.</description>
    <arm_group_label>Placebo then Metolazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stable chronic kidney disease patients able to provide consent&#xD;
&#xD;
          -  stable dialysis patients who produce urine and able to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use of antibiotics for last two months or expected antibiotic use&#xD;
&#xD;
          -  recent hospitalization or other event resulting in instability of food intake&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tammy L Sirich, MD</last_name>
    <phone>650-493-5000</phone>
    <phone_ext>68321</phone_ext>
    <email>tsirich@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tammy Sirich, MD</last_name>
      <phone>650-493-5000</phone>
      <phone_ext>68321</phone_ext>
      <email>tsirich@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Sirich, MD</last_name>
      <phone>650-493-5000</phone>
      <phone_ext>68321</phone_ext>
      <email>tsirich@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Tammy Lisa Sirich</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metolazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

